Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2020-01-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于抗缪勒氏管激素检测试剂盒产品获得医疗器械注册证（体外诊断试剂）的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (687 characters) about the company Anhui Anke Biological Engineering (Group) Co., Ltd. obtaining a medical device registration certificate for a new product (anti-Mullerian hormone test kit). It is a regulatory announcement about product approval and market launch, not a financial report or detailed filing. There is no financial data, no mention of shareholder votes, no management changes, no earnings or annual report content. The document is an official company announcement regarding regulatory approval of a product, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-01-07 Chinese
国元证券股份有限公司关于公司2019年持续督导培训情况的报告
Audit Report / Information Classification · 90% confidence The document is a report from a sponsoring institution (国元证券股份有限公司) about the continuous supervision training conducted for the company 安徽安科生物工程(集团)股份有限公司 in 2019. It details the training content, participants, and summary of the training session. There is no financial data, no mention of financial results, no voting results, no management changes, no legal proceedings, no capital changes, and no earnings information. The document is a specific report on a regulatory or compliance training activity related to ongoing supervision by the sponsor. It is not an annual or interim report, nor an announcement or presentation. Given the nature of the document as a report on regulatory training and supervision, it fits best under Audit Report / Information (AR), which includes results of internal or regulatory stress tests and applied accounting principles, and can extend to regulatory compliance reports by sponsors. The document length is short but contains substantive content, so it is not a mere announcement (RPA) or regulatory filing (RNS). Therefore, the best classification is AR with high confidence. FY 2019
2020-01-07 Chinese
关于两项精浆检测试剂盒产品获得医疗器械注册证（体外诊断试剂）的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval and registration of two new medical diagnostic reagent products by the Anhui Provincial Drug Administration. It details the product names, their clinical uses, and the impact on the company's product line and market competitiveness. There is no financial data, no mention of financial results, no shareholder voting information, no management changes, no legal proceedings, or any other regulatory filing typical of financial or corporate governance reports. The document is a regulatory announcement about product registration and approval, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement or certification. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-01-07 Chinese
独立董事关于第七届董事会第一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the appointment of senior management and board members at the company's seventh board meeting. It discusses the election and appointment of the chairman, vice chairman, senior vice presidents, vice presidents, financial director, and other senior management roles. The document references compliance with company law, stock exchange guidelines, and internal company rules. It does not contain financial statements or results, nor is it a report or announcement of voting results. It is clearly related to board and management information, specifically the announcement of changes in senior management and board positions.
2019-12-26 Chinese
关于选举产生第七届监事会职工监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of employee representative supervisors to the company's seventh supervisory board. It includes details about the elected individuals, their qualifications, shareholdings, and compliance with relevant laws and regulations. There is no financial data, no mention of financial results, no report publication, or any other type of report. The content focuses on board/management information, specifically about the supervisory board composition. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2019-12-26 Chinese
关于董事会、监事会完成换届选举及聘任高级管理人员、内部审计负责人的公告
Board/Management Information Classification · 100% confidence The document is an official announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the completion of the board of directors and supervisory board re-election, as well as the appointment of senior management and internal audit personnel. It details the election results, lists the members of the new board and committees, and provides information on the term expirations and departures of previous members. The content focuses on changes in the company's board and senior management personnel, which aligns with the category for announcements of changes in the company's board of directors or senior management. The document is not a full report, financial statement, or presentation, but a formal announcement of management changes.
2019-12-26 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.